[10-Q] Odysight.ai Inc. Quarterly Earnings Report

Q: What were Odysight.ai's revenues and net loss for the six months ended June 30, 2025?

Revenues were $2.427 million and net loss was $8.34 million for the six months ended June 30, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

10-Q

Rhea-AI Filing Summary

Odysight.ai Inc. reported interim condensed results showing increased liquidity after a U.S. public offering and an expanded Nasdaq listing, alongside continued operating losses. Cash and restricted cash rose to $33.2 million at June 30, 2025, after gross proceeds of approximately $23.7 million from the offering and net proceeds of about $20.9 million. Revenue for the six months was $2.427 million (up 77%), driven largely by derecognition of a customer fulfillment asset, while gross profit was $671 thousand.

Despite revenue growth, the company recorded a net loss of $8.34 million for the six months and an accumulated deficit of $54.3 million. Management states existing cash is expected to fund operations for at least the next 12 months. Remaining performance obligations (backlog) were approximately $14.4 million. Key risks disclosed include customer concentration, outstanding warrants of 5.763 million shares, exposure to geopolitical disruption in Israel and potential U.S. tariffs affecting imports.

Positive

Net proceeds of approximately $20.9 million from a U.S. public offering, strengthening liquidity
Cash and restricted cash of $33.2 million at June 30, 2025, providing runway management expects for at least 12 months
Nasdaq Capital Market listing under the ticker ODYS, improving market access and visibility
Remaining performance obligations (backlog) of ~$14.4 million, reflecting booked future revenue

Negative

Net loss of $8.34 million for the six months ended June 30, 2025 and an increased operating loss of $8.998 million
Accumulated deficit of $54.3 million, indicating prolonged historical losses
Revenue volatility and customer concentration: derecognition of fulfillment asset (~$1.69M) tied to a Fortune 500 medical customer and no 2025 purchase order
Quarterly revenue decline: three months ended June 30, 2025 revenue fell to $362K (down 69% YoY) driven by reduced units to the medical customer
Outstanding warrants of 5.763 million potential shares and option activity could cause dilution
Operational risks disclosed include geopolitical conflict in Israel and potential U.S. import tariffs that may raise costs

Insights

TL;DR: Nasdaq listing and $20.9M net proceeds materially improve liquidity but elevated losses and customer concentration keep near-term outlook mixed.

Liquidity improved materially with cash and restricted cash of $33.2M following a public offering that generated net proceeds of ~$20.9M. This provides runway the company expects will cover operations for at least 12 months. Revenue growth for the six months to $2.427M was largely attributable to derecognition of a fulfillment asset related to a Fortune 500 medical customer, which masks underlying sales trends. Operating and net losses widened to $8.998M and $8.34M respectively for the six months, driven by higher R&D, sales and G&A spend. Warrants and option activity imply potential dilution; management reported 5.763M warrants outstanding. Overall impact: material liquidity improvement but continued cash burn and concentration risks warrant caution.

TL;DR: Financial and operational risks are significant: increasing losses, customer concentration and geopolitical exposure could materially affect execution.

The company recorded an accumulated deficit of $54.3M and increased operating loss versus prior year. A single large customer relationship drove deferred assets that were derecognized when a 2025 purchase order did not materialize, highlighting revenue concentration risk and inventory/asset impairment (~$1.69M derecognition and $203K inventory impairment). The filing discloses operational disruptions from regional conflict and potential U.S. tariffs that may raise import costs. Contractual backlog/RPO is ~$14.4M, down slightly from year-end, and operating lease obligations total about $1M. These factors collectively represent a material risk profile for near-term performance.

08/13/2025 - 04:06 PM

false Q2 --12-31 0001577445 0001577445 2025-01-01 2025-06-30 0001577445 2025-08-13 0001577445 2025-06-30 0001577445 2024-12-31 0001577445 us-gaap:RelatedPartyMember 2025-06-30 0001577445 us-gaap:RelatedPartyMember 2024-12-31 0001577445 us-gaap:NonrelatedPartyMember 2025-06-30 0001577445 us-gaap:NonrelatedPartyMember 2024-12-31 0001577445 2024-01-01 2024-06-30 0001577445 2025-04-01 2025-06-30 0001577445 2024-04-01 2024-06-30 0001577445 us-gaap:CommonStockMember 2024-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001577445 us-gaap:RetainedEarningsMember 2024-12-31 0001577445 us-gaap:CommonStockMember 2025-03-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001577445 us-gaap:RetainedEarningsMember 2025-03-31 0001577445 2025-03-31 0001577445 us-gaap:CommonStockMember 2023-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001577445 us-gaap:RetainedEarningsMember 2023-12-31 0001577445 2023-12-31 0001577445 us-gaap:CommonStockMember 2024-03-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001577445 us-gaap:RetainedEarningsMember 2024-03-31 0001577445 2024-03-31 0001577445 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001577445 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001577445 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001577445 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001577445 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001577445 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001577445 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001577445 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001577445 us-gaap:CommonStockMember 2025-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001577445 us-gaap:RetainedEarningsMember 2025-06-30 0001577445 us-gaap:CommonStockMember 2024-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001577445 us-gaap:RetainedEarningsMember 2024-06-30 0001577445 2024-06-30 0001577445 2025-02-01 2025-02-28 0001577445 ODYS:LeaseAgreementMember 2020-12-01 2020-12-31 0001577445 ODYS:LeaseAgreementMember 2023-01-25 2023-01-25 0001577445 ODYS:LeaseAgreementMember 2023-05-01 2023-05-31 0001577445 2023-05-01 2023-05-31 0001577445 ODYS:OfficeLeaseMember 2025-06-30 0001577445 us-gaap:InvestorMember 2021-03-28 2021-03-29 0001577445 us-gaap:InvestorMember 2021-03-29 0001577445 ODYS:StockPurchaseAgreementsMember 2023-03-15 2023-03-16 0001577445 ODYS:StockPurchaseAgreementsMember 2023-03-16 0001577445 us-gaap:CommonStockMember 2024-07-16 2024-07-16 0001577445 us-gaap:CommonStockMember 2024-07-16 0001577445 ODYS:UnderwritingAgreementMember ODYS:UnderwritersMember 2025-02-12 2025-02-12 0001577445 ODYS:UnderwritingAgreementMember ODYS:UnderwritersMember 2025-02-12 0001577445 us-gaap:OverAllotmentOptionMember 2025-02-14 2025-02-14 0001577445 us-gaap:OverAllotmentOptionMember 2025-02-14 0001577445 us-gaap:CommonStockMember 2025-02-14 2025-02-14 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-02-01 2020-02-29 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2020-03-14 2020-03-15 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-06-22 2020-06-22 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2021-04-01 2021-06-30 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2023-01-01 2023-03-31 0001577445 ODYS:TwoThousandAndTwentyFourShareIncentivePlanMember ODYS:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-02-01 2020-02-29 0001577445 ODYS:TwoThousandAndTwentyShareIncentivePlanMember ODYS:BoardOfDirectorsMember 2024-07-01 2024-07-31 0001577445 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0001577445 ODYS:WarrantMarchTwoThousandTwentyOneMember 2025-01-01 2025-06-30 0001577445 ODYS:WarrantMarchTwoThousandTwentyOneMember 2025-06-30 0001577445 ODYS:WarrantMarchTwoThousandTwentyThreeMember 2025-01-01 2025-06-30 0001577445 ODYS:WarrantMarchTwoThousandTwentyThreeMember 2025-06-30 0001577445 us-gaap:WarrantMember 2025-06-30 0001577445 us-gaap:StockOptionMember 2024-12-31 0001577445 us-gaap:StockOptionMember 2025-01-01 2025-06-30 0001577445 us-gaap:StockOptionMember 2025-06-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2025-06-30 0001577445 us-gaap:CostOfSalesMember 2025-01-01 2025-06-30 0001577445 us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0001577445 us-gaap:CostOfSalesMember 2025-04-01 2025-06-30 0001577445 us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0001577445 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-06-30 0001577445 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001577445 us-gaap:ResearchAndDevelopmentExpenseMember 2025-04-01 2025-06-30 0001577445 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001577445 us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-06-30 0001577445 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001577445 us-gaap:SellingAndMarketingExpenseMember 2025-04-01 2025-06-30 0001577445 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-06-30 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2025-04-01 2025-06-30 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001577445 ODYS:RelatedDevelopmentCostsMember 2025-06-30 0001577445 ODYS:DevelopmentAndManufacturingServicesMember 2025-01-01 2025-06-30 0001577445 2024-01-01 2024-12-31 0001577445 us-gaap:CorporateMember 2025-01-01 2025-06-30 0001577445 us-gaap:CorporateMember 2024-01-01 2024-06-30 0001577445 us-gaap:CorporateMember 2025-04-01 2025-06-30 0001577445 us-gaap:CorporateMember 2024-04-01 2024-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-42497

ODYSIGHT.AI INC.

(Exact name of registrant as specified in its charter)

Nevada		47-4257143
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)

Suite 7A, Industrial Park
P.O. Box 3030, Omer, Israel		8496500
(Address of Principal Executive Offices)		(Zip Code)

+972 73 370-4690

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.001 per share		ODYS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☐	Large accelerated filer	☐	Accelerated filer
☒	Non-accelerated filer	☒	Smaller reporting company
		☐	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 13, 2025, the registrant had 16,330,827 shares of common stock, par value $0.001 of the registrant issued and outstanding.

As used in this Quarterly Report and unless otherwise indicated, the terms “Odysight.ai,” “we,” “us,” “our,” or “our Company” refer to Odysight.ai. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

ODYSIGHT.AI INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page

Special Note Regarding Forward-Looking Statements		3

PART 1-FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements (unaudited)	4

	Consolidated Balance Sheets	5

	Consolidated Statements of Comprehensive Loss	7

	Statements of Stockholders’ Equity	8

	Consolidated Statements of Cash Flows	10

	Notes to Consolidated Financial Statements	12

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	28

Item 4.	Control and Procedures	28

PART II-OTHER INFORMATION

Item 1.	Legal proceedings	29

Item 1A.	Risk Factors	29

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 3.	Defaults Upon Senior Securities	29

Item 4.	Mine Safety Disclosures	29

Item 5.	Other information	29

Item 6.	Exhibits	30

SIGNATURES		31

-2-

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

	●	our ability to scale up upon our operations, including market acceptance of our vision-based sensor products;

	●	the amount and timing of future sales;

	●	our ability to meet technical and quality specifications;

	●	our ability to accurately estimate the future supply and demand for the Odysight TruVision solution and changes to various factors in our supply chain;

	●	the market for adoption of vision-based sensor technologies;

	●	existing regulations and regulatory developments in the United States and other jurisdictions;

	●	our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others;

	●	the need to hire additional personnel and our ability to attract and retain such personnel;

	●	our estimates regarding expenses, backlog, future revenue, capital requirements and need for additional financing;

	●	our dependence on third parties;

	●	our financial performance;

	●	the growth of regulatory requirements and incentives;

	●	risks related to product liability claims or product recalls;

	●	the overall global economic environment and trade tensions, including the adoption or expansion of economic sanctions, tariffs or trade restrictions;

	●	the impact of competition and new technologies;

	●	our plans to continue to invest in research and develop technology for new products;

	●	our plans to potentially acquire complementary businesses;

	●	the impact of any resurgence of COVID-19 or any of its variants or any other pandemic on our business and on the business of our customers;

	●	security, political and economic instability in the Middle East that could harm our business, including due to the current war in Israel; and

	●	the increased expenses associated with being a listed public company on the Nasdaq Capital Market, or Nasdaq.

Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Important factors that may cause actual results to differ materially from current expectations including, among other things, those listed under “Risk Factors” our Annual Report on Form 10-K for the year ended December 31, 2024 (filed on March 26, 2025). Readers are urged to consider these factors carefully in evaluating the forward-looking statements. You should read our Annual Report on Form 10-K for the year ended December 31, 2024, and the documents that we reference in and have filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2024, completely and with the understanding that our actual future results may be materially different from what we expect.

Forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this Quarterly Report on Form 10-Q. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the Securities and Exchange Commission (“SEC”) after the date of this Quarterly Report on Form 10-Q. We qualify all of our forward-looking statements by these cautionary statements.

-3-

Item 1. Financial Statements

ODYSIGHT.AI INC.

INTERIM FINANCIAL STATEMENTS

AS OF JUNE 30, 2025

CONSOLIDATED ODYSIGHT.AI INC.

	Page
Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands
Interim Condensed Consolidated Balance Sheets (unaudited)	5
Interim Condensed Consolidated Statements of Operations (unaudited)	7
Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)	8
Interim Condensed Consolidated Statements of Cash Flows (unaudited)	10
Notes to the Interim Condensed Consolidated Financial Statements	12

-4-

ODYSIGHT.AI INC.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,		December 31,
	2025		2024
	Unaudited		Audited
	USD in thousands
Assets

CURRENT ASSETS:
Cash and cash equivalents		32,910		18,164
Restricted cash		328		-
Restricted deposit		-		322
Accounts receivable		509		1,510
Inventory		-		203
Other current assets		1,138		588
Total current assets		34,885		20,787

NON-CURRENT ASSETS:
Contract fulfillment assets		-		1,017
Property and equipment, net		379		407
Operating lease right-of-use assets		919		1,113
Severance pay asset		280		259
Other non-current assets		96		96
Total non-current assets		1,674		2,892

TOTAL ASSETS		36,559		23,679

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

-5-

ODYSIGHT.AI INC.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

	June 30,			December 31,
	2025			2024
	Unaudited			Audited
	USD in thousands
Liabilities and shareholders’ equity

CURRENT LIABILITIES:
Accounts payable		554			442
Contract liabilities - short term		279			702
Operating lease liabilities - short term		538			539
Accrued compensation expenses		1,329			1,124
Related parties		155			120
Other current liabilities		439			368
Total current liabilities		3,294			3,295

NON-CURRENT LIABILITIES:
Contract liabilities - long term		-			1,373
Operating lease liabilities - long term		381			508
Liability for severance pay		280			259
Total non-current liabilities		661			2,140

TOTAL LIABILITIES		3,955			5,435

SHAREHOLDERS’ EQUITY:
Common stock, $0.001 par value; 300,000,000 shares authorized as of June 30, 2025 and December 31, 2024, 16,326,656 and 12,612,517 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively		17			13
Additional paid-in capital		86,901			64,205
Accumulated deficit		(54,314	)		(45,974	)
TOTAL SHAREHOLDERS’ EQUITY		32,604			18,244

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		36,559			23,679

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

-6-

ODYSIGHT.AI INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	2025			2024			2025			2024
	Six months ended June 30,						Three months ended June 30,
	2025			2024			2025			2024
	Unaudited
	USD in thousands

REVENUES		2,427			1,368			362			1,181
COST OF REVENUES		1,756			1,077			229			667
GROSS PROFIT		671			291			133			514
RESEARCH AND DEVELOPMENT EXPENSES		4,843			2,975			2,356			1,408
SALES AND MARKETING EXPENSES		1,024			459			628			225
GENERAL AND ADMINISTRATIVE EXPENSES		3,802			2,585			1,587			1,245
OPERATING LOSS		(8,998	)		(5,728	)		(4,438	)		(2,364	)
FINANCING INCOME, NET		658			384			363			182
NET LOSS		(8,340	)		(5,344	)		(4,075	)		(2,182	)
Net loss per ordinary share (basic and diluted, USD)		(0.54	)		(0.51	)		(0.25	)		(0.21	)
Weighted average ordinary shares (basic and diluted, in thousands)		15,450			10,447			16,316			10,449

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

-7-

ODYSIGHT.AI INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

Six Months Ended June 30, 2025 (Unaudited)

	Number		Amount		capital			deficit			equity
	Common Stock				Additional paid-in			Accumulated			Total Shareholders’
	Number		Amount		capital			Deficit			equity
	In thousands		USD in thousands
Balance at January 1, 2025		12,613	$	13	$	64,205			(45,974	)	$	18,244
Stock based compensation		-		-		1,651			-			1,651
Issuance of shares upon RSU vesting
Issuance of shares upon RSU vesting		5		-*		-(*	)		-			-
Issuance of shares, net of issuance cost		3,653		4		20,863			-			20,867
Options exercise		56		-*		182			-			182
Net loss		-		-		-			(8,340	)		(8,340	)
Balance at June 30, 2025		16,327	$	17	$	86,901		$	(54,314	)	$	32,604

Three Months Ended June 30, 2025 (Unaudited)

	Common Stock				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		Deficit			equity
	In thousands		USD in thousands
Balance as of April 1, 2025		16,308	$	17	$	85,987	$	(50,239	)	$	35,765
Stock based compensation		-		-		845		-			845
Options exercise		19		-		69		-			69
Net loss		-		-		-		(4,075	)		(4,075	)
Balance as of June 30, 2025		16,327	$	17	$	86,901	$	(54,314	)	$	32,604

*	Represents an amount less than $1 thousand

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

-8-

Six Months Ended June 30, 2024 (Unaudited)

	Common Stock				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		Deficit			equity
	In thousands		USD in thousands
Balance as of January 1, 2024		10,444	$	10	$	52,004	$	(34,207	)	$	17,807
Stock based compensation		-		-		963		-			963
Issuance of shares upon RSU vesting		14		-*		-(*)		-			-
Net loss		-		-		-		(5,344	)		(5,344	)
Balance as of June 30, 2024		10,458	$	10	$	52,967	$	(39,551	)	$	13,426

Three Months Ended June 30, 2024 (Unaudited)

	Common Stock				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		Deficit			equity
	In thousands		USD in thousands
Balance as of April 1, 2024		10,447	$	10	$	52,504	$	(37,369	)	$	15,145
Balance		10,447	$	10	$	52,504	$	(37,369	)	$	15,145
Stock based compensation		-		-		463		-			463
Issuance of shares upon RSU vesting		11		-*		-(*)		-			-
Net loss		-		-		-		(2,182	)		(2,182	)
Balance as of June 30, 2024		10,458	$	10	$	52,967	$	(39,551	)	$	13,426
Balance		10,458	$	10	$	52,967	$	(39,551	)	$	13,426

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

-9-

ODYSIGHT.AI INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	2025			2024			2025			2024
	Six months ended June 30,						Three months ended June 30,
	2025			2024			2025			2024
	Unaudited
	USD in thousands

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		(8,340	)		(5,344	)		(4,075	)		(2,182	)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation		58			64			31			31
Stock based compensation		1,651			963			845			463
Interest from operating lease liability		-			(42	)		16			(25	)
Loss (profit) from exchange differences		(42	)		40			(71	)		19
Interest income in respect of deposits		12			96			-			228

Changes in operating assets and liability items:
Decrease (increase) in accounts receivable		1,023			614			(295	)		(635	)
Decrease in inventory		203			65			-			165
Severance pay asset and liability		-			(13	)		-			(13	)
Decrease in operating lease liability		(242	)		(226	)		(122	)		(112	)
Decrease in right-of-use asset		239			227			121			118
Increase in other current and non-current assets		(527	)		(225	)		(423	)		(95	)
Increase (decrease) in account payable		126			5			117			(107	)
Increase (decrease) in related parties		35			1			(63	)		3
Decrease in contract fulfillment assets		1,017			120			-			60
Increase (decrease) in current and non-current contract liabilities		(1,796	)		(127	)		36			(52	)
Increase (decrease) in accrued compensation expenses		122			419			(210	)		66
Increase (decrease) in other current and non-current liabilities		58			40			(77	)		(25	)
Net cash flows used in operating activities		(6,403	)		(3,323	)		(4,170	)		(2,093	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment		(30	)		(30	)		(3	)		(8	)
Withdrawal of short terms deposits		310			8,000			-			8,000
Net cash flows provided by (used in) investing activities		280			7,970			(3	)		7,992

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net of issuance cost		20,874			-			(35	)		-
Proceeds from options exercise		182						69
Net cash flows provided by financing activities		21,056			-			34			-

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		14,933			4,647			(4,139	)		5,899
BALANCE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD		18,164			8,945			37,207			7,672
EFFECT FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		141			(40	)		170			(19	)
BALANCE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT THE END OF THE PERIOD		33,238			13,552			33,238			13,552

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:
Cash and cash equivalents		32,910			13,238			32,910			13,238
Restricted cash		328			314			328			314
Total cash, cash equivalents and restricted cash		33,238			13,552			33,238			13,552

-10-

Non-cash activities -

	Six months ended June 30,						Three months ended June 30,
	2025			2024			2025			2024
	Unaudited
	USD in thousands

SUPPLEMENTAL INFORMATION FOR CASH FLOW:
Right-of-use assets obtained in exchange for operating lease liabilities		78			120			78			33
Termination of right-of-use assets in exchange for cancellation of operating lease obligations		(33	)		(55	)		(33	)		(24	)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

-11-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL:

	a.	Odysight.ai Inc (the “Company”) was incorporated under the laws of the State of Nevada on March 22, 2013.

		The Company’s wholly owned subsidiary, Odysight.ai Ltd (“Odysight.ai”), was incorporated in the State of Israel on January 3, 2019, and was merged into the Company on December 31, 2019 in a share exchange transaction, following which the surviving operations of the merged entity were the operations of Odysight.ai.

		On February 28, 2024, D. VIEW Ltd., a wholly owned subsidiary of the Company was incorporated in the State of Israel to act as a local representative for the defense market in Israel.

		On January 9, 2025, Odysight.Ai Eu S.r.l., a wholly owned subsidiary of the Company was incorporated under the laws of Italy.

		References to the Company include the subsidiaries unless the context indicates otherwise.

		The Company, through its subsidiaries, provides vision-based platform solutions for the Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets with its visualization and AI platform. The Company’s video sensor-based solutions and its embedded software, and AI algorithms are deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases and allow maintenance and operations teams visibility into areas which are inaccessible under normal operation, or where the operating ambience is not suitable for continuous real-time monitoring. Some of the Company’s products utilize micro visualization technology in medical devices for minimally invasive medical procedures. In February 2025, we closed a public offering generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting commissions and estimated offering expenses. After deducting issuance costs, the Company received proceeds of approximately $20.9 million. For additional information see note 5(a)(4).

		On February 11, 2025, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”. Prior to such date, the Company was quoted on the OTCQB under the same symbol.

-12-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continued):

Since incorporation of Odysight.ai and through June 30, 2025, the Company accumulated a deficit of approximately $54.3 million and its activities have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources will allow the Company to fund its operating plan through at least the next 12 months from the filing date of these interim condensed financial statements. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations, requiring the Company to obtain additional funding to continue its future operations until becoming profitable.

On June 13, 2025, Israel launched “Operation Rising Lion” with a surprise attack on Iran, including precision strikes on weapon and nuclear facilities. In response to Israel’s attack, Iran launched retaliatory strikes on Israel, which included significant ballistic missiles and unmanned aerial vehicles fired towards both military and civilian targets in Israel. The attacks resulted in Israeli civilian casualties and property damage.

Consequently, Israel’s Home Front Command announced a “special home front situation” and imposed stricter safety guidelines than had previously been in place, such as restricting public gatherings and passenger flights to and from Israel, and the temporary closure of certain businesses, which led to a decrease in market and economic activity in Israel.

As a result of these guidelines, the Company’s offices in Israel were closed on certain days during this period. The Company does not expect a substantial impact on its operations from the above-described events.

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

a. Unaudited Interim Financial Statements

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

b. Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

c. Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment and stock-based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.

-13-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):

d. Significant Accounting Policies

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

NOTE 3 – LEASES:

Omer office space

In December 2020, Odysight.ai entered into a lease agreement for office space in Omer, Israel (the “original space”), with the 36-month term for such agreement beginning on January 1, 2021. In March 2021, Odysight.ai entered into a lease agreement for additional office space in Omer, Israel (the “additional space”), with the term for such agreement ending December 31, 2023.

On June 25, 2023, Odysight.ai entered into an amendment to these agreements, pursuant to which the lease for the additional space was shortened and ended on June 30, 2023 and the lease for the original space was extended for an additional five years until December 31, 2028. It was also agreed that Odysight.ai has an option to terminate the agreement for the original space after three years. Odysight.ai expects that the lease period will be three years.

Monthly lease payments under the agreement for the original space are approximately $7 thousand.

Ramat Gan office space

In May 2023, Odysight.ai entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 48 months beginning on July 1, 2023 and the Company has an option to extend the lease period for an additional two years. The Company currently does not expect to extend the lease period. Monthly lease payments under the agreement are approximately $25 thousand.

Odysight.ai subleases part of the office space in Ramat Gan to a third party for approximately $8 thousand per month.

The Company leases vehicles for the use of certain of its employees in Israel. The lease terms are typically three-year periods.

Supplemental cash flow information related to operating leases was as follows:

	2025		2024		2025		2024
	Six months ended June 30,				Three months ended June 30,
	2025		2024		2025		2024
	Unaudited
	USD in thousands

Cash paid for amounts included in the measurement of lease liabilities		296		297		149		146

As of June 30, 2025, the Company’s operating leases had a weighted average remaining lease term of 0.60 years and a weighted average discount rate of 6% for vehicles and 12.8% for offices.

The maturities of lease liabilities under operating leases as of June 30, 2025, are as follows:

	Operating leases
	USD in thousands
Remainder of 2025		301
2026		505
2027		201
2028		3
Total future lease payments		1,010
Less imputed interest		(91	)
Total lease liability balance		919

-14-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – OTHER CURRENT LIABILITIES:

Other current liabilities consisted of the following:

SCHEDULE OF OTHER CURRENT LIABILITIES

	June, 2025		December 31, 2024
	USD in thousands
Government authorities		85		79
Accrued expenses		326		261
Other payables		28		28
Total other current liabilities		439		368

NOTE 5 – EQUITY:

	a.	Private Placement

	1.	On March 29, 2021, the Company issued to certain investors, including Moshe (Mori) Arkin, a major stockholder and director of the Company, an aggregate of 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consisted of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock with an exercise price of $10.35 per share. Each such warrant is exercisable until March 31, 2026 and subject to customary adjustments. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of the Company’s common stock equals or exceeds 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise.

	2.	On March 16, 2023, the Company entered into stock purchase agreements for a private placement with (i) Moshe (Mori) Arkin and (ii) The Phoenix Insurance Company Ltd. (“Phoenix Insurance”) and Shotfut Menayot Israel – Phoenix Amitim (“Phoenix Amitim”), in connection with the sale and issuance of an aggregate of 3,294,117 units, at a purchase price of $4.25 per unit, and for an aggregate purchase price of $14 million. Each unit consisted of: (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock. The warrants are immediately exercisable, expire three years from the date of issuance and are subject to customary adjustments.

	3.	On July 16, 2024, the Company issued 2,144,583 shares of its common stock in consideration for a purchase price of $4.80 per share to new and existing investors, including Moshe (Mori) Arkin and The Phoenix Holdings, through Phoenix Insurance and Phoenix Amitim (the “2024 Private Placement”). The Company raised approximately $10.3 million (gross) in the 2024 Private Placement. After deducting issuance costs, the Company received proceeds of approximately $9.8 million.

	4.	On February 12, 2025, the Company completed a U.S. underwritten public offering issuing 3,307,692 shares of the Company’s common stock at a price of $6.50 per share. The Company also granted the underwriters a 30-day over-allotment option to purchase up to an additional 496,153 shares at a purchase price of $6.50 per share. On February 14, 2025, the Company sold an additional 345,432 shares of common stock as a result of a partial exercise of the over-allotment option at the public offering price of $6.50 per share. Following the exercise of the over-allotment option, the Company sold a total of 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting discounts, commissions and estimated offering expenses. After deducting issuance costs, the Company received proceeds of approximately $20.9 million.

Warrants:

As of June 30, 2025, the Company had the following outstanding warrants to purchase common stock:

Warrant

Issuance
Date

Expiration
Date

Exercise Price
Per Share
($)

Number of
Underlying
Common Stocks

March 2021 Warrants

March 29, 2021

March 31, 2026

10.35

2,469,156

March 2023 Warrants

March 27, 2023

March 26, 2026

5.50

3,294,117

5,763,273

-15-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 – EQUITY (continued):

b. Stock-based compensation for employees, directors and service providers:

In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “2020 Plan”).

The 2020 Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 777,778 shares of common stock. During the first quarter of 2023, the Company’s Board of Directors approved an increase to the option pool pursuant to the 2020 Plan by an additional 1,000,000 shares of common stock.

In June 2024, the Company’s Board of Directors approved the 2024 Share Incentive Plan (the “2024 Plan”). With adoption of the 2024 Plan, the Company ceased making new awards under the 2020 Plan.

The 2024 Plan initially included a pool of 234,484 shares of common stock, representing the number of shares remaining available for grant under the 2020 Plan. These shares are available for future grant to Company employees, consultants, directors and other service providers. Shares that were subject to awards granted under either the 2020 Plan or the 2024 Plan that have expired or were cancelled or become un-exercisable for any reason without having been exercised in full shall become available for future grant under the 2024 Plan.

In July 2024, the Company’s Board of Directors approved an increase to the 2024 Plan’s option pool by an additional 850,000 shares of common stock.

Also in July 2024, stockholders approved the 2024 Plan.

The 2020 Plan and 2024 Plan each provide for the grant of stock options (including incentive stock options and nonqualified stock options), shares of common stock, restricted shares, restricted share units, and other share-based awards.

Stock option activity

The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:

	Six months ended
	June 30, 2025
Underlying value of ordinary shares ($)		5.12
Exercise price ($)		6.50
Expected volatility (%)		99.65	%
Term of the options (years)		7
Risk-free interest rate		4.10	%

The cost of the benefit embodied in the options granted during the six months ended June 30, 2025, based on their fair value as of the grant date, is estimated to be approximately $926 thousand. These amounts will be recognized in the statements of operations and comprehensive income over the vesting period.

The following table summarizes stock option activity for the six months ended June 30, 2025:

SCHEDULE OF STOCK OPTION ACTIVITY

	For the
	Six months ended
	June 30, 2025
	Number of			Weighted average
	Options			exercise price ($)
Outstanding at beginning of period		3,227,234			3.78
Granted		181,000			6.5
Exercised		(58,101	)		3.27
Forfeited		(28,336	)		4.09
Outstanding at end of period		3,321,797			3.94

Vested at end of period		2,035,607			3.52

-16-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 – EQUITY (continued):

Restricted stock unit (“RSU”) activity

Each RSU vests based on continued service to the Company, generally over three years. The grant date fair value of the award is recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.

The following table summarizes RSU activity for the six months ended June 30, 2025:

SCHEDULE OF STOCK OPTION ACTIVITY

	For the
	Six months ended
	June 30, 2025
	Number of			Weighted Average Grant Date Fair Value
	RSUs			per Share ($)
Outstanding at beginning of period		15,419			3.56
Granted		-			-
Forfeited		-			-
Vested		(7,085	)		4.21
Unvested and Outstanding at end of period		8,334			3

The following table sets forth the total stock-based payment expenses resulting from options and RSUs granted, included in the statements of operation and comprehensive income:

SCHEDULE OF STOCK-BASED PAYMENT EXPENSE

	2025			2024		2025		2024
	Six months ended June 30,					Three months ended June 30,
	2025			2024		2025		2024
	Unaudited
	USD in thousands

Cost of revenues		(3	)		17		-		8
Research and development		466			225		219		90
Sales and marketing expenses		202			95		99		45
General and administrative		986			626		527		320
Total expenses		1,651			963		845		463

-17-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 – REVENUES:

Disaggregation of revenue:

	(1)	During the second quarter of 2022, the Company completed the development of a customer-specific project for a Fortune 500 medical company customer (the “Client”) and moved from the project development phase to its production phase. Through June 30, 2025, the Company recognized development services revenues and costs that had been previously deferred based on the expected manufacturing term of the product, which the Company estimated originally at seven years. During the first quarter of 2025, due to the fact that the Company has not received a purchase order from the Client and does not expect to receive such order, the Company decided to fully derecognize the fulfillment asset and contract liability associated with the Client, in the amount of $1,690 thousand and $957 thousand, respectively.
	(2)	During the six months ended June 30, 2025, the Company recognized revenues from customization and development services in which the performance obligation is satisfied over time in the amount of $569 thousand.

Contract fulfillment assets and Contract liabilities:

The Company’s contract fulfillment assets and contract liabilities as of June 30, 2025, and December 31, 2024, were as follows:

	June 30,		December 31,
	2025		2024
	USD in thousands
Contract fulfillment assets		-		1,017
Contract liabilities		279		2,075

Contract liabilities include deferred service and advance payments.

The change in contract fulfillment assets:

	June 30,			December 31,
	2025			2024
	USD in thousands
Balance at beginning of the period		1,017			1,256
Contract fulfillment assets, Balance at beginning of the period		1,017			1,256
Contract costs recognized during the period		(1,017	)		(239	)
Balance at end of the period		-			1,017
Contract fulfillment assets, Balance at end of the period		-			1,017

The change in contract liabilities:

	June 30,			December 31,
	2025			2024
	USD in thousands
Balance at beginning of the period		2,075			2,322
Contract liabilities, Balance at beginning of the period		2,075			2,322
Deferred revenue relating to new sales		178			253
Revenue recognized during the period		(1,974	)		(500	)
Balance at end of the period		279			2,075
Contract liabilities, Balance at end of the period		279			2,075

Remaining Performance Obligations

Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be invoiced and recognized as revenue in future periods. As of June 30, 2025, the total RPO amounted to approximately $14.4 million.

-18-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 - INVENTORY:

Composed as follows:

SCHEDULE OF INVENTORY

	June 30,		December 31,
	2025		2024
	USD in thousands
Raw materials and supplies		-		172
Work in progress		-		19
Finished goods		-		12
Inventory gross		-		203

For the six months ended June 30, 2025, the Company recognized an inventory impairment related to the Client in the amount of $203 thousand. See Note 6a(1).

NOTE 8 – LOSS PER SHARE

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares as described below.

Basic net loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the common stock considered outstanding during the year, in accordance with ASC 260-10 “Earnings per Share”.

All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the period, since all such securities have an anti-dilutive effect.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

On April 2023, the Company received approval from the Israel Innovation Authority (the “IIA”) to support and enhance the Company’s production line and capabilities in the next 24 months until April 2025. Pursuant to the agreement with the IIA relating to the program, the Company is required pay royalties of 3% to the IIA up to the amount IIA funding received and the accrued interest repayment of the grant is contingent upon the Company successfully completing its enhancement plans and generating sales from the enhancements performed. The Company has no obligation to repay these grants if its enhancement plans are not completed or aborted or if it generates no sales.

-19-

ODYSIGHT.AI INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 – SEGMENT REPORTING

Segment information is prepared on the same basis that the chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes business decisions and assesses performance. The Company has one reportable segment specializing in vision-based platform solutions as described in Note 1.

The chief executive officer assesses performance for this segment and decides how to allocate resource. The measure of segment assets is reported on the balance sheet as total assets. The chief executive officer performs the assessment of segment performance by using the reported measure of segment profit or loss to monitor budget versus actual results.

The table below summarizes the significant expense categories regularly reviewed by the chief operating decision maker, for the six months and three months ended June 30, 2025 and 2024:

	2025			2024			2025			2024
	Six months ended June 30,						Three months ended June 30,
	2025			2024			2025			2024
	Unaudited
	USD in thousands

Revenues		2,427			1,368			362			1,181

Cost of Sales (*)		1,749			1,038			229			649

Research and Development expenses (*)		4,340			2,722			2,112			1,303

Sales and marketing (*)		820			364			527			180

General and Administrative expenses (*)		2,807			1,945			1,056			919

Other segment items:
Stock-based payments		1,651			963			845			463
Depreciation		58			64			31			31
Finance income, net		658			384			363			182

Net loss		(8,340	)		(5,344	)		(4,075	)		(2,182	)

(*)

Excluding stock-based payments and depreciation expenses.

NOTE 11 – SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued and identified no subsequent events as of the date that the financial statements were issued.

-20-

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report for the year ended December 31, 2024 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We were incorporated under the laws of the State of Nevada on March 22, 2013, under the name Intellisense Solutions Inc.

On December 30, 2019, we acquired all of the issued and outstanding share capital of ScoutCam Ltd. and, on December 31, 2029, we changed our name to ScoutCam Inc. Following this acquisition, we integrated and fully adopted the acquired miniaturized imaging business into us as our primary business activity. On June 5, 2023, we changed our name to Odysight.ai Inc.

We are a pioneer in the development, production and marketing of an innovative visualization and artificial intelligence, or AI, solution that deploys small cameras to monitor critical safety components in hard-to-reach locations and harsh environments, across various Predictive Maintenance, or PdM, and Condition Based Monitoring, or CBM, use cases.

The Odysight TruVision solution streams visual information to our processing unit, an in-platform, high-performance AI/machine learning computer, allowing maintenance and operations teams, on the ground and during operations, visibility into areas that are inaccessible under normal operating conditions or where conditions are not suitable for continuous real-time monitoring. The rich and informative data, continuously collected and analyzed by our solution on our secured cloud, provides customers with real-time failure / anomaly detection, events and data recordings, interfacing with platform mission systems and providing real-time alerts and streaming video or images, all while training our algorithms for ongoing improved accuracy and prediction capabilities. Our customers benefit from increased safety, a reduction in downtime and lower maintenance costs for their monitored platforms, using the prediction capabilities of our solution to efficiently plan maintenance work on monitored components.

Our solution aims to enhance safety and minimizes downtime by enabling real-time visual analysis of any failure occurrences. Additionally, we leverage advanced big data analytics to offer predictive insights throughout the entire system lifecycle. This includes efficient spare parts management and intelligent performance predictions, ensuring optimal system reliability and efficiency.

The Odysight TruVision solution was successfully used by NASA as we seek to reshape the aerospace, Industry 4.0, transportation and energy markets with a vison-based technology leveraging AI and machine learning to deliver innovative solutions that transform maintenance practices. As used in this Quarterly Report on Form 10-Q, Industry 4.0, or I4.0, refers to the integration of advanced technologies into manufacturing and industrial processes to create smart, interconnected systems for improved efficiency and productivity.

Odysight solutions are already deployed in the aviation and medical sectors. Our customers include the Israeli Air Force, the Israeli Ministry of Defense, France-based Safran Aircraft Engines, a global international defense contractor, a leading Fortune 500 medical company as well as NASA, who came back to us for a repeat order. Historically, our revenue stream has been derived mainly from the medical sector. We have secured several contracts for our PdM and CBM systems with major government clients and defense and aviation companies and our backlog as of June 30, 2025 of approximately $14.4 million reflects mostly those contracts.

As we have not received a purchase order for 2025 from the Fortune 500 medical company customer and do not expect to receive such order, we decided, during the first quarter of 2025, to fully derecognize the fulfillment asset and contract liability associated with this customer.

-21-

Public Offering and Nasdaq Listing

In February 2025, we closed a public offering, including the exercise of an over-allotment option granted to the underwriter in the public offering. The public offering and the over-allotment option exercise price was $6.50 per share. In the aggregate, we sold a total of 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting discounts, commissions and estimated offering expenses. After deducting issuance costs, we received proceeds of approximately $20.9 million. Also in February 2025, our common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”.

Impact of the Ongoing War in Israel on Our Business

On October 7, 2023, the Hamas terrorist organization launched a series of deadly terror attacks on civilian and military targets skirting the Gaza Strip in the southern part of Israel and fired rockets on many of the communities in southern and central Israel. Following the attack, Israel’s security cabinet declared war and commenced a military campaign in Gaza against Hamas. Since the outbreak of the war, the Hezbollah terrorist organization has regularly fired rockets into northern Israel and, in October 2024, Israel invaded southern Lebanon in response to these attacks. On November 27, 2024, Israel and Lebanon agreed to a ceasefire, the result of which is uncertain. During the course of the war, other terrorist organizations have fired rockets into Israel, such as various rebel militia groups in Syria and Iraq and the Houthi movement, which controls parts of Yemen. The Houthis movement has also attacked commercial shipping vessels in the Gulf of Aden and Red Sea. In addition, following two direct attacks by Iran on Israel in 2024 involving hundreds of drones and missiles, the two countries fought a 12-day war in June 2025 that was triggered by large-scale preemptive Israeli airstrikes on Iranian nuclear and military sites. Iran retaliated with significant ballistic missile and drone attacks on Israel, leading to direct U.S. military intervention against Iranian nuclear sites before a U.S.-brokered ceasefire was declared.

The war has had significant economic, military and social consequences to Israel. To date the war has not had a material adverse effect on our business. While we have offices in Omer and Ramat Gan, Israel, neither of our sites is located near Israel’s relevant borders where the main impact of the war has been felt. Nevertheless, we have experienced some minor disruptions to our routine work, including some difficulties in traveling outside of Israel and occasional rocket fire on the municipalities where our offices are located, requiring our employees to take temporarily shelter for a few minutes at a time in on-site safe rooms. Pursuant to instructions from Israel’s Home Front Command, the Company’s offices were closed on certain days during the war with Iran. In addition, several of our executives and employees, including company officers such as our CEO, were called up to military reserve duty. As of the date of this Quarterly Report on Form 10-Q, our CEO is subject to military reserve duty a few days a month. We have taken various measures to mitigate the effects of the war, including adopting work-from-home measures, increased employee overtime and third-party outsourcing where needed, and reviewing our business continuity plan. In addition, with the backdrop of the ongoing conflict, some of our clients and potential clients have not prioritized conducting transactions with us, and the war may have caused some delays in their finalizing purchase orders. We do not believe that such delays have had a material impact on our business. The war has also increased negative sentiments regarding Israel and Israeli companies in the international community. For example, Israeli defense companies were initially banned from participating in prestigious industry conferences in France during 2024; however, both bans were later overturned by French courts and did not impact our participation in such conferences.

Conversely, as a result of the intensive flight hours flown by all Israeli Air Force platforms as a result of the war and an enhanced Israel Ministry of Defense budget, we have experienced a growing interest in our technology from Israeli clients, including government agencies and R&D programs, which may lead to more rapid assimilation of our technology into relevant platforms than we had anticipated prior to the commencement of the war, positively affecting on our business activity. For additional information, see “Risks Related to our Operations in Israel – Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel” in our Annual Report on Form 10-K for the year ended December 31, 2024.

Comparison of the six months ended June 30, 2025 and 2024

The following table summarizes our results of operations for the six months period ended June 30, 2025 and 2024, together with the changes in those items in dollars in thousands and as a percentage:

	Six months ended June 30,
	2025			2024			% Change
Revenues		2,427			1,368			77	%
Cost of Revenues		1,756			1,077			63	%
Gross Profit		671			291			131	%
Research and development expenses		4,843			2,975			63	%
Sales and marketing expense		1,024			459			123	%
General and administrative expenses		3,802			2,585			47	%
Operating Loss		(8,998	)		(5,728	)		57	%

-22-

Revenues

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

For the six months ended June 30, 2025, we generated revenues of $2,427 thousand, an increase of $1,059 thousand, or 77%, compared to $1,368 thousand for the six months ended June 30, 2024.

The increase in revenue was primarily due to the full derecognition of the contract liability associated with the Fortune 500 medical company customer, in the amount of $1,690 thousand, as described in Note 6a(1) to our interim consolidated financial statements for the six months ended June 30, 2025, and to an increase in revenues from our vision-based platform solutions for PdM and CBM. The increase in revenue was partially offset by decrease in the number of units sold and supplied to the Fortune 500 medical company customer due to the absence of a purchase order for 2025, as described in Note 6a(1) to our interim consolidated financial statements for the six months ended June 30, 2025.

Cost of Revenues

Cost of revenue is primarily comprised of cost of personnel, certain allocated expenses related to facilities, logistics and quality control.

Cost of revenues for the six months ended June 30, 2025 was $1,756 thousand, an increase of $679 thousand, or 63%, compared to cost of revenues of $1,077 thousand for the six months ended June 30, 2024.

The increase in cost of revenues was primarily due to the full derecognition of the fulfillment asset associated with the Fortune 500 medical company customer, in the amount of $957 thousand, to the recognition of an inventory impairment of $203 thousand, as described in Note 6a(1) to our interim consolidated financial statements for the six months ended June 30, 2025, and to an increase in revenues from our vision-based platform solutions for PdM and CBM. The increase in cost of revenues was partially offset by decrease in the number of units sold and supplied to the Fortune 500 medical company customer due to the absence of a purchase order for 2025, as described in Note 6a(1) to our interim consolidated financial statements for the six months ended June 30, 2025.

Gross Profit

Gross profit for the six months ended June 30, 2025, was $671 thousand, an increase of $380 thousand, or 131%, compared to gross profit of $291 thousand for the six months ended June 30, 2024.

The change in gross profit was due to an increase in revenues, partially offset by an increase in cost of revenues, as described above.

Research and Development Expenses

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting, and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, including expenses for rent and maintenance of our facilities, utilities, depreciation and other supplies. We expense research and development costs as incurred.

Research and development expenses for the six months ended June 30, 2025, were $4,843 thousand, an increase of $1,868 thousand, or 63%, compared to $2,975 thousand for the six months ended June 30, 2024.

The increase in research and development expenses was mainly due to the development of new products and the resulting increase in payroll and related expenses related to the recruitment of new employees, an increase in stock-based compensation from new option grants and procuring materials and services of subcontractors for Industry 4.0 projects.

We expect that our research and development expenses will increase as we continue to develop our products and services and recruit additional research and development employees due to increased focus on R&D activities in the I4.0 domain.

-23-

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of payroll and related expenses, consulting services, promotional materials, exhibitions, demonstration equipment and certain allocated facility infrastructure costs.

Sales and marketing expenses for the six months ended June 30, 2025, were $1,024 thousand, an increase of $565 thousand, or 123%, compared to $459 thousand for the six months ended June 30, 2024.

The increase in sales and marketing expenses was primarily driven by tour efforts to penetrate new markets and enhance product visibility. This led to higher payroll and related expenses associated with the recruitment of new employees, an increase in stock-based compensation due to newly granted options and additional expenses resulting from the engagement of new marketing consultants and participation in various exhibitions.

We expect that our sales and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain

General and Administrative Expenses

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services and insurance costs.

General and administrative expenses for the six months ended June 30, 2025, were $3,802 thousand, an increase of $1,217 thousand, or 47%, compared to $2,585 thousand for the six months ended June 30, 2024.

The increase in general and administrative expenses was primarily due to:

	-	an increase in payroll and related expenses due to the recruitment of new employees, including a CFO, and cash compensation bonuses paid to senior executives;
	-	expenses related to our fund raising and uplisting to Nasdaq; and
	-	an increase in stock-based compensation from new option grants.

Operating loss

We incurred an operating loss of $8,998 thousand for the six months ended June 30, 2025, an increase of $3,270 thousand or 57%, compared to operating loss of $5,728 thousand for the six months ended June 30, 2024.

The increase in operating loss was due to increases in research and development expenses, general and administrative expenses and sales and marketing expenses, each as described above, partially offset by an increase in gross profit.

Cash Flows

Our primary uses of cash used in operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services costs and costs related to our facilities. We expect that cash flows from operating activities will continue to increase due to an expected increase in the expenses of our business and our working capital requirements.

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars in thousands):

	Six month ended June 30,
	2025			2024
Cash used in Operating Activity		(6,403	)		(3,323	)
Cash provided by Investing Activity		280			7,970
Cash provided by Financing Activity		21,056			-

Operating Activities

During the six months ended June 30, 2025, cash used in operating activities was $6.4 million, consisting of net loss of $8.3 million, partially offset by a favorable net change in operating assets and liabilities of $0.2 million and a non-cash benefit of $1.7 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in accounts receivable and a decrease in contract fulfillment assets, partially offset by outflows from changes in current and non-current other assets and a decrease in current and non-current contract liabilities.

During the six months ended June 30, 2024, cash used in operating activities was $3.3 million, consisting of net loss of $5.3 million, partially offset by a favorable net change in operating assets and liabilities of $0.9 million and a non-cash benefit of $1.1 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash outflows from changes in contract liability and other current assets, partially offset by inflows from changes in accounts payables and other accounts payables.

-24-

Investing Activities

During the six months ended June 30, 2025, cash provided by investing activities was $0.3 million, attributable mainly to a withdrawal, net of short-term deposits.

During the six months ended June 30, 2024, cash provided by investing activities was $8.0 million, attributable mainly to a withdrawal, net of short-term deposits.

Financing Activities

During the six months ended June 30, 2025, cash provided by financing activities was $21.1 million, consisting of cash proceeds from issuance of shares, net of issuance costs and proceeds from options exercise.

Comparison of the three months ended June 30, 2025 and 2024

The following table summarizes our results of operations for the three months period ended June 30, 2025, and 2024, together with the changes in those items in dollars in thousands and as a percentage:

	Three months ended June 30,
	2025			2024			% Change
Revenues		362			1,181			(69	)%
Cost of Revenues		229			667			(66	)%
Gross Profit		133			514			(74	)%
Research and development expenses		2,356			1,408			67	%
Sales and marketing expense		628			225			179	%
General and administrative expenses		1,587			1,245			27	%
Operating Loss		(4,438	)		(2,364	)		88	%

Revenues

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

For the three months ended June 30, 2025, we generated revenues of $362 thousand, a decrease of $819 thousand, or 69%, compared to $1,181 thousand for the three months ended June 30, 2024.

The decrease in revenues was primarily attributable to the decrease in revenues from the Fortune 500 medical company customer, partially offset by an increase in revenues from our vision-based platform solutions for PdM and CBM.

Cost of Revenues

Cost of revenue is primarily comprised of cost of personnel, certain allocated expenses related to facilities, logistics and quality control.

Cost of revenues for the three months ended June 30, 2025, was $229 thousand, a decrease of $438 thousand, or 66%, compared to cost of revenues of $667 thousand for the three months ended June 30, 2024.

The decrease in cost of revenues was mainly due to decrease in revenues, as described above.

Gross Profit

Gross profit for the three months ended June 30, 2025, was $133 thousand, a decrease of $381 thousand, or 74%, as compared to the three months ended June 30, 2024.

The change in gross profit was due to both a decrease in revenues and a decrease in cost of revenues, as described above.

-25-

Research and Development Expenses

Research and development expenses for the three months ended June 30, 2025 were $2,356 thousand, an increase of $948 thousand, or 67%, compared to $1,408 thousand for the three months ended June 30, 2024.

The increase in research and development expenses was mainly due to the development of new products and the resulting increase in payroll and related expenses for new employees’ recruitment, an increase in stock-based compensation from new option grants and procuring materials and services of subcontractors for Industry 4.0 projects.

Sales and Marketing Expenses

Sales and marketing expenses for the three months ended June 30, 2025, were $628 thousand, an increase of $403 thousand, or 179%, compared to $225 thousand for the three months ended June 30, 2024.

The increase in sales and marketing expenses was primarily driven by our efforts to penetrate new markets and enhance product visibility. This led to higher payroll and related expenses associated with the recruitment of new employees, an increase in stock-based compensation due to newly granted options and additional expenses resulting from the engagement of new marketing consultants and participation in various exhibitions.

We expect that our sales and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain

General and Administrative Expenses

General and administrative expenses for the three months ended June 30, 2025, were $1,587 thousand, an increase of $342 thousand, or 27% compared to $1,245 thousand for the three months ended June 30, 2024.

The increase in general and administrative expenses was primarily due to an increase in stock-based compensation from new option grants.

Operating loss

We incurred an operating loss of $4,438 thousand for the three months ended June 30, 2025, an increase of $2,074 thousand, or 88%, compared to operating loss of $2,364 thousand for the three months ended June 30, 2024.

The increase in operating loss was due to a decrease in gross profit and increases in research and development expenses, general and administrative expenses and sales and marketing expenses, each as described above.

-26-

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars in thousands):

	Three month ended June 30,
	2025			2024
Cash used in Operating Activity		(4,170	)		(2,093	)
Cash provided by (used in) Investing Activity		(3	)		7,992
Cash provided by Financing Activity		34			-

Operating Activities

During the three months ended June 30, 2025, cash used in operating activities was $4.2 million, consisting of net loss of $4.1 million, an unfavorable net change in operating assets and liabilities of $1.0 million and a non-cash benefit of $0.9 million. Our non-cash benefit consisted primarily of non-cash charges of $0.8 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash outflows from changes in accounts receivable, lease liability, current and non-current assets and accrued compensation.

During the three months ended June 30, 2024, cash used in operating activities was $2.1 million, consisting of net loss of $2.2 million, an unfavorable net change in operating assets and liabilities of $0.6 million and a non-cash benefit of $0.7 million. Our non-cash benefit consisted primarily of non-cash charges of $0.5 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash outflows from changes in accounts receivable.

Investing Activities

For the three months ended June 30, 2025, net cash flows used in investing activities was $3 thousand, attributable to a purchase of property and equipment.

For the three months ended June 30, 2024, net cash flows provided by investing activities was $8 million, attributable mainly to a withdrawal, net on short-term deposits.

Financing Activities

For the three months ended June 30, 2025, net cash flows provided by financing activities was $34 thousand, consisting of proceeds from options exercise, partially offset by issuance expenses.

Backlog

Backlog represents booked orders based on purchase orders or hard commitments but not yet recognized as revenue. Orders included in backlog may be cancelled or rescheduled by customers. A variety of conditions, both specific to the individual customer and generally affecting the customer’s industry, may cause customers to cancel, reduce or delay orders that were previously made or anticipated. We cannot assure the timely replacement of cancelled, delayed or reduced orders. Backlog is presented for supplemental informational purposes only and is not intended to be a substitute for any GAAP financial measures, including revenue or net income (loss), and, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. In addition, backlog should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Therefore, backlog should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.

Our backlog as of June 30, 2025 was approximately $14.4 million compared to approximately $15.0 million as of December 31, 2024.

Liquidity and Capital Resources

As of June 30, 2025, we had cash and cash equivalents and restricted cash of $33.2 million compared to cash and cash equivalents and restricted deposit of $18.5 million as of December 31, 2024. In addition, as of June 30, 2025, we incurred an accumulated deficit of $54.3 million compared to $46 million as of December 31, 2024.

In February 2025, we closed a public offering, including the exercise of an over-allotment option granted to the underwriter in the public offering, at a price of $6.50 per share. In the aggregate, we issued 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting commissions and estimated offering expenses.

Our primary sources of liquidity to date have been from fund-raising, revenues from customers and warrant exercises.

Additional Cash Requirements

We plan to continue to invest in long-term growth, and therefore we expect that our expenses will grow. We currently believe that our existing cash and cash equivalents and short-term deposits will allow us to fund our operating plan through at least the next 12 months from the date of this report. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research and development and the scale up Odysight TruVision solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we may need to raise additional capital before we become profitable from sales of our solutions and may do so to expand our business, pursue strategic investments, take advantage of financing opportunities or for other reasons. We may raise these funds through equity financing, debt financing or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

-27-

Contractual Obligations and Commitments

Operating lease payments represent our commitment for future rent made leases for our offices in Israel and for vehicle leasing. The total future payments for our operating lease obligation as of June 30, 2025 were approximately $1 million. For additional details regarding our lease, see Note 3 to our interim consolidated financial statements for the six months ended June 30, 2025.

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter ended June 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

-28-

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS.

Except for the additional risk factor provided below, there have been no material changes from the information set forth in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 26, 2025.

The U.S. trade tariffs implemented in 2025 may increase the costs of importing our products into the U.S. and increase our supply chain costs which could potentially reduce profit margins and affect our competitive position.

Our current products are manufactured outside the United States, and, as a result, the U.S. trade tariffs implemented by President Donald Trump in 2025 may increase the costs associated with importing our finished products into the U.S. Although we believe that such tariffs will not have a material impact on our business operations, the additional cost on goods imported to the U.S. as a result of the tariffs could directly affect our profit margins when borne by us, or, when borne by our U.S. customers, could effectively lead to a higher purchase price for our customers. Such an increase may drive our customers to seek local alternatives that do not carry the tariff burden, potentially decreasing the demand for our products and affecting our market share. Additionally, the U.S. trade tariffs may increase our supply chain costs, including the cost of components sourced from our suppliers in various countries due to abrupt supply and demand shifts. As a result of the consequences of this tariff policy, we may need to obtain components from other sources or third parties. Furthermore, the uncertainty and volatility introduced by these tariffs complicate decision making, planning and forecasting for our customers as well as for us, making it more difficult to predict future costs and financial outcomes accurately. The potential for further U.S. tariff changes and retaliatory tariffs or other actions by affected countries, and the increased volatility in global financial markets that could result, may exacerbate these challenges, making it difficult for us to predict future costs and financial outcomes accurately. Any of these factors may reduce our profit margins and affect our competitive position.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended June 30, 2025, we did not have any sales of unregistered securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

On August 13, 2025, the Company entered into a revised Director Appointment and Service Agreement with Jackson Schneider. Under the revised agreement, Mr. Schneider’s annual fee for service on the board of directors will increase from $80,000 to $120,000, which will be paid on a monthly basis in equal installments, and the Company will recommend that the board of directors grant Mr. Schneider options to purchase a total of 50,000 shares of common stock, at an exercise price per share that will be determined at the sole discretion of the Board and shall be subject to provisions of the applicable equity incentive plan under which the options are granted, and vesting over a period of three years. In addition, the revised agreement provides that Mr. Schneider will receive a one-time commission for initiating or facilitating new commercial agreements between the Company and certain pre-approved third parties (“Eligible Customers”), such as major OEMs. The commission is based on actual net revenue generated from these new agreements (“Qualifying Transactions”) and is structured as follows: 2% commission on net revenue up to $250 million, 1.5% commission on net revenue between $250 million and $400 million, and 1% commission on net revenue exceeding $400 million. The list of Eligible Customers is to be mutually agreed upon and updated quarterly in writing. Commissions are paid within 30 days after the Company receives the applicable net revenue, which is defined as actual revenue received and recognized by the Company, less third-party costs, applicable taxes and any conditional payments until such conditions are satisfied. No commission is payable if a Qualifying Transaction is canceled, and any previously paid commission must be refunded. “Qualifying Transactions” are defined as new (not follow-on) commercial agreements for Company products, resulting solely from Mr. Schneider’ efforts.

During the quarter ended June 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).

-29-

ITEM 6. EXHIBITS.

(a)

The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.

Exhibit Number		Description
3.1.1		Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1.1 to our Form S-1 filed with the SEC on July 17, 2023)

3.2.1		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed with the SEC on June 8, 2023)

10.1*		Director Appointment and Service Agreement of Jackson Schneider, dated August 13, 2025

31.1*		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act

31.2*		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act

32.1**		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document

101.INS		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

*		Filed herewith.

**		Furnished herewith.

-30-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2025	ODYSIGHT.AI INC

	By:	/s/ Yehu Ofer
	Name:	Yehu Ofer
	Title:	Chief Executive Officer
		Odysight.ai Inc

	By:	/s/ Einav Brenner
	Name:	Einav Brenner
	Title:	Chief Financial Officer
		Odysight.ai Inc

-31-

Source: View Original Filing on SEC EDGAR

FAQ

How much cash did Odysight.ai (ODYS) have at June 30, 2025?

As of June 30, 2025, Odysight.ai reported total cash and restricted cash of $33.238 million (cash and equivalents $32.91 million plus restricted cash $0.328 million).

What were Odysight.ai's revenues and net loss for the six months ended June 30, 2025?

Revenues were $2.427 million and net loss was $8.34 million for the six months ended June 30, 2025.

How much did Odysight.ai raise in its public offering and what were net proceeds?

The company sold 3,653,124 shares for gross proceeds of approximately $23.7 million and received net proceeds of about $20.9 million after issuance costs.

What backlog or remaining performance obligations does Odysight.ai report?

Remaining performance obligations (backlog) were approximately $14.4 million as of June 30, 2025.

Does Odysight.ai disclose risks related to Israel or tariffs?

Yes. The filing discloses potential operational impacts from geopolitical conflict in Israel and notes U.S. trade tariffs in 2025 could increase import and supply chain costs.

[10-Q] Odysight.ai Inc. Quarterly Earnings Report

Insights

FAQ

How much cash did Odysight.ai (ODYS) have at June 30, 2025?

What were Odysight.ai's revenues and net loss for the six months ended June 30, 2025?

How much did Odysight.ai raise in its public offering and what were net proceeds?

What backlog or remaining performance obligations does Odysight.ai report?

Does Odysight.ai disclose risks related to Israel or tariffs?

NASDAQ:ODYS

ODYS Rankings

ODYS Latest News

ODYS Latest SEC Filings

ODYS Stock Data

Trending News

[10-Q] Odysight.ai Inc. Quarterly Earnings Report

Insights

Securities Analyst neutral

Risk Analyst negative

FAQ

How much cash did Odysight.ai (ODYS) have at June 30, 2025?

What were Odysight.ai's revenues and net loss for the six months ended June 30, 2025?

How much did Odysight.ai raise in its public offering and what were net proceeds?

What backlog or remaining performance obligations does Odysight.ai report?

Does Odysight.ai disclose risks related to Israel or tariffs?

NASDAQ:ODYS

ODYS Rankings

ODYS Latest News

ODYS Latest SEC Filings

ODYS Stock Data